Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial

Contraception

Volumn 79, Issue 2, 2009, Pages 111-116

  Cagnacci, Angelo ^a   Ferrari, Serena ^a   Tirelli, Alessandra ^a   Zanin, Renata ^a   Volpe, Annibale ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Chlormadinone acetate; Contraception; Desogestrel; Insulin; Metabolism; Progesterone

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CHLORMADINONE ACETATE; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTRADIOL; ETHINYLESTRADIOL; FOLLITROPIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; ENZYME MODIFICATION; FEMALE; GLUCOSE UTILIZATION; HUMAN; INSULIN RESPONSE; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER FUNCTION; NORMAL HUMAN; ORAL CONTRACEPTION;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-PEPTIDE; CHLORMADINONE ACETATE; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER FUNCTION TESTS; LUTEINIZING HORMONE; YOUNG ADULT;

EID: 58149147337     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.09.002     Document Type: Article

References (41)

1. De Fronzo R.A., and Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
2. Reaven G.M., Lithell H., and Landsberg L. Hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympathoadrenal system. N Engl J Med 334 (1996) 375-381
3. Després J.P., Lamarche B., Mauriége P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 (1996) 952-957
4. De Pirro R., Fusco A., Bertoli A., Greco A.V., and Lauro R. Insulin receptors during the menstrual cycle in normal women. J Clin Endocrinol Metab 47 (1978) 1387-1389
5. Diamond M.P., Simonson D.C., and De Fronzo R.A. Menstrual cyclicity has a profound effect on glucose homeostasis. Fertil Steril 52 (1989) 204-208
6. Valdes C., and Helkind-Hirsch K. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab 72 (1991) 642-645
7. Helkind-Hirsch K.E., Sherman L.D., and Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab 76 (1993) 472-475
8. Lindheim S.R., Presser S.C., Ditkoff E.C., ViJod M.A., Stanczyk F.Z., and Lobo R.A. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60 (1993) 664-667
9. ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 16 (2001) 1527-1535
10. De Pirro R., Forte F., Bertoli A., Greco A.V., and Lauro R. Changes in insulin receptors during oral contraception. J Clin Endocrinol Metab 52 (1981) 29-33
11. Kasdorf G., and Kalkhoff R.K. Prospective studies of insulin sensitivity in normal women receiving oral contraceptive agents. J Clin Endocrinol Metab 66 (1988) 846-852
12. Skouby S.O., Andersen O., and Saurberey N. Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes. J Clin Endocrinol Metab 64 (1987) 519-523
13. Godsland I.F., Walton C., Felton C., Proudler A., Patel L.A., and Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 74 (1992) 64-70
14. Gaspard U.J., Demeyer F., Jaminet C.B., Scheen A.J., and Lefebvre P.J. Influence of two low dose oral contraceptives containing ethinylestradiol (20 mcg) and desogestrel or gestodene on carbohydrate metabolism during 1 year of use. Gynecol Endocrinol 10 Suppl 1 (1996) 179-181
15. Petersen K.R., Christiansen E., Madsbad S., Skouby S.O., Andersen L.F., and Jespersen J. Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. Contraception 60 (1999) 337-344
16. Cagnacci A., Paoletti A.M., Renzi A., et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptive containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 88 (2003) 3621-3625
17. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 47 (2004) 277-283
18. Cohen J.C., and Hickman R. Insulin resistance and decreased tolerance in powelifters ingesting anabolic steroids. J Clin Endocrinol Metab 64 (1987) 960-963
19. Holmag A., Larsson B.M., Brzezinska M., and Bjorntorp P. Effects of short-term testosterone exposure on insulin sensitivity of muscle in female rats. Am J Physiol 262 (1992) E851-E855
20. Polderman K.H., Gooren L.J.G., Asscheman H., Bakker A., and Hein R.J. Induction of insulin resistance by estrogens and androgens. J Clin Endocrinol Metab 79 (1994) 265-271
21. Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol 192 (2007) 585-594
22. Ciaraldi T.P., el-Roeiy A., Madar Z., Reichart D., Olefsky J.M., and Yen S.S.C. Cellular mechanisms of insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 75 (1992) 577-583
23. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997) 774-800
24. Dahlgren E., Landin K., Krotkiewski M., Holm G., and Janson P.O. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 13 (1998) 2706-2711
25. Cagnacci A., Paoletti A.M., Arangino S., Melis G.B., and Volpe A. Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism. Hum Reprod 14 (1999) 893-897
26. Moghetti P., Tosi F., Castello R., et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 81 (1996) 952-960
27. Raudrant D., and Rabe T. Progestogens with antiandrogenic properties. Drugs 63 (2003) 463-492
28. Pélissier C., Basdevant A., Conard J., Egloff M., Husson T., and Guyenne T.T. Contraception progestative par l' acétate de chlormadinone chez des femmes à risqué vasculaire: (étude gynéco-endocrinienne, métabolique et vasculaire). Contracept Fertil Steril 15 (1987) 45-54
29. Schamm G., and Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara). Drugs Invest 22 (2002) 221-231
30. Welch S., Gebhart S.S.P., and Bergman R.N. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71 (1990) 1508-1518
31. American Diabetes Association Consensus Development Conference on Insulin Resistance 1998. Diabetes Care 21 (1998) 310-314
32. Cagnacci A., Arangino S., Renzi A., Cagnacci P., and Volpe A. Insulin sensitivity in women: a comparison among values derived from intravenous glucose tolerance tests with different sampling frequency, oral glucose tolerance test or fasting. Eur J Endocrinol 145 (2001) 281-287
33. Cagnacci A., Tirelli A., Cannoletta M., Pirillo D., and Volpe A. Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis. Contraception 72 (2005) 443-446
34. Cagnacci A., Soldani R., Carriero P.L., Paoletti A.M., Fioretti P., and Melis G.B. Effect of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 74 (1992) 1396-1400
35. Bonora E., Zavaroni I., Coscelli C., and Butturini U. Decreased hepatic insulin extraction in subjects with mild glucose intolerance. Metabolism 32 (1983) 438-446
36. Wahl P., Walden R., Knopp R., et al. Effects of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 308 (1983) 862-867
37. Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms estrogen. Contraception 46 (1992) 477-488
38. Song S., Chen J.K., Yang P.J., et al. A cross-over study of three oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel. Contraception 45 (1992) 523-532
39. Akerlund M., Almstrom E., Hogstedt S., and Nabrink M. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet Gynecol Scand 73 (1994) 136-143
40. Van der Mooren M.J., Klipping C., van Aken B., Helmerhorst E., Spielmann D., and Kluft C. A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care 4 Suppl 2 (1999) 27-35
41. Curram M.P., and Wagstaff A.J. Ethinylestradiol/chlormadinone acetate. Drugs 64 (2004) 751-760